Login / Signup

Publicly subsidised smoking cessation medicines in times of COVID-19 in Australia: An interrupted time series analysis.

Dolly O BaliunasCoral E GartnerSamantha A HollingworthClair SullivanTracy A ComansJason D Pole
Published in: Drug and alcohol review (2022)
There has been a differential change in the number of subsidised smoking cessation medicines supplied in Australia since the COVID-19 pandemic, with varenicline prescriptions largely within, and NRT patches largely lower than, expected ranges. The reasons for the apparent change in dispensing of subsidised smoking cessation medicines are unclear.
Keyphrases
  • smoking cessation
  • replacement therapy
  • coronavirus disease
  • sars cov
  • diffusion weighted imaging